Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 May;23(5):444-50.
doi: 10.1089/hum.2011.167. Epub 2012 Jan 17.

Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies

Partow Kebriaei  1 , Helen Huls, Bipulendu Jena, Mark Munsell, Rineka Jackson, Dean A Lee, Perry B Hackett, Gabriela Rondon, Elizabeth Shpall, Richard E Champlin, Laurence J N Cooper
Affiliations
Clinical Trial

Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies

Partow Kebriaei et al. Hum Gene Ther. 2012 May.

Abstract

Limited curative treatment options exist for patients with advanced B-lymphoid malignancies, and new therapeutic approaches are needed to augment the efficacy of hematopoietic stem-cell transplantation (HSCT). Cellular therapies, such as adoptive transfer of T cells that are being evaluated to target malignant disease, use mechanisms independent of chemo- and radiotherapy with nonoverlapping toxicities. Gene therapy is employed to generate tumor-specific T cells, as specificity can be redirected through enforced expression of a chimeric antigen receptor (CAR) to achieve antigen recognition based on the specificity of a monoclonal antibody. By combining cell and gene therapies, we have opened a new Phase I protocol at the MD Anderson Cancer Center (Houston, TX) to examine the safety and feasibility of administering autologous genetically modified T cells expressing a CD19-specific CAR (capable of signaling through chimeric CD28 and CD3-ζ) into patients with high-risk B-lymphoid malignancies undergoing autologous HSCT. The T cells are genetically modified by nonviral gene transfer of the Sleeping Beauty system and CAR(+) T cells selectively propagated in a CAR-dependent manner on designer artificial antigen-presenting cells. The results of this study will lay the foundation for future protocols including CAR(+) T-cell infusions derived from allogeneic sources.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Berry L.J. Moeller M. Darcy P.K. Adoptive immunotherapy for cancer: The next generation of gene-engineered immune cells. Tissue Antigens. 2009;74:277–289. - PubMed
    1. Bonini C. Ferrari G. Verzeletti S., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719–1724. - PubMed
    1. Brady T. Roth S.L. Malani N., et al. A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res. 2011;39:e72. - PMC - PubMed
    1. Brenner M.K. Heslop H.E. Adoptive T cell therapy of cancer. Curr. Opin. Immunol. 2010;22:251–257. - PMC - PubMed
    1. Brentjens R. Yeh R. Bernal Y., et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: Case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 2010;18:666–668. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources